On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Ebola virus
- Ebola virus GP (glycoprotein)
- GP structure
- GP crystallization
- Final crystallization construct
- Physiological relevance
- Final crystals
- GP crystal structure
- GP structure (360 view)
- GP trimer interface
- How is GP assembled?
- GP1 and GP2 subdomains
- GP1 base domain (1)
- GP1 base domain (2)
- GP1 head domain
- GP1 glycan cap
- GP2 N terminus
- GP2 internal fusion loop
- GP2 heptad repeat 1
- Three HR1D subunits form the trimer interface
- Three internal fusion loops wrap around the trimer
- GP function in attachment, fusion and entry
- GP residues important for attachment
- Putative receptor binding sites
- Glycan caps
- Biantennary glycans
- Mucin-like domain make GP 5-12 times bigger
- When and how does the RBS come into play?
- How is the RBS exposed?
- Probable cathepsin cleavage site
- After cleavage with cathepsin
- Hypothesis for entry
- Model for entry
- What is left exposed for immune surveillance?
- Survivor Fab KZ52 neutralizes in vitro
- Three KZ52 Fabs bound to GP trimer
- KZ52 is primarily an anti-GP2 antibody
- Effect of KZ52
- KZ52 bridges N term of GP2, IFL of GP2, and GP1
- GP amino acids interacting with KZ52
- Sudan ebolavirus (1)
- Sudan ebolavirus (2)
- Crystals of Sudan ebolavirus GP
- Sudan ebolavirus GP bound to the 16F6 mAb
- KZ52 and 16F6 binding sites overlap
- How might Abs against the shared site neutralize?
- What are those conformational changes?
- Prefusion and postfusion GPs
- Possible conformational changes at fusion (1)
- Possible conformational changes at fusion (2)
- Thanks
Topics Covered
- Structure of Zaire ebolavirus GP Receptor binding
- Cathepsin cleavage
- Immune evasion Structure of Sudan ebolavirus GP
- GP epitopes of two neutralizing antibodies
- Proposed conformational changes in fusion
Links
Categories:
Therapeutic Areas:
Talk Citation
Ollmann Saphire, E. (2011, March 30). A shared structural solution for neutralizing ebolaviruses [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 17, 2025, from https://doi.org/10.69645/TEGG2723.Export Citation (RIS)
Publication History
- Published on March 30, 2011
Financial Disclosures
- Dr. Erica Ollmann Saphire has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.